Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA advisory committee votes against approving GSK’s mepolizumab to treat COPD
GSK said the committee voted on the basis of data presented that the risk-benefit profile was not adequate to support approval In addition, the committee noted that there
GSK said the committee voted on the basis of data presented that the risk-benefit profile was not adequate to support approval In addition, the committee noted that there
The trial is one of the two phase 1 safety clinical studies of the drug examining its potential to cause dermal irritation. XF-73 is Destiny Pharma’s lead candidate
The study achieved its primary endpoint at the first pre-specified interim analysis, with Alunbrig showing a statistically significant improvement in PFS compared against crizotinib in adults with anaplastic
The company will build the new multi-storey and 400,000ft² production facility in Portage, situated in Kalamazoo County. Named as modular aseptic processing (MAP), the new production facility will
The proof-of-concept study will assess the efficacy and safety of sulfatinib as a monotherapy in patients with advanced BTC, whose condition has progressed on standard first-line chemotherapy, and
TRX518 is a humanized monoclonal antibody with agonist activity that has been designed to target the glucocorticord-inducible TNF-superfamily receptor (GITR). The GITR agonist has been engineered to improve
The acquisition will allow Cambrex to enter the dosage form CDMO market. Halo Pharma is majority owned by funds managed by the private investment firm SK Capital Partners.
Tibsovo, which is an oral and targeted inhibitor of the IDH1 enzyme, is said to be the first and only FDA-approved therapy for patients with R/R AML and